Answers are grounded in this paper and cite their sources.
Analysis of non-industry orphan designations reveals lower marketing authorization rates for rare diseases, suggesting a need for regulatory support.
• Of 2,734 orphan designations, 183 (6.7%) were granted to non-industry organizations. • Protocol assistance rates for non-industry organizations were similar to industry (33% vs. 35%) • Marketing authorization rates were lower for non-industry than for industry (3.3% vs. 13%) • As of now, the probability of marketing authorization after 22 years was 16% for non-industry vs. 23% for industry. • Protocol assistance requests peaked in years when grant calls required regulatory interactions. Non-industry organizations, including academia, charities, and public institutes, increasingly contribute to rare disease medicine development. In this study, we reviewed orphan designations (ODs) granted between 2000 and 2022, comparing non-industry and industry outcomes. Of 2734 ODs, 183 (6.7%) originated from non-industry organizations. Protocol assistance was obtained for 33% of non-industry and 35% of industry ODs, with distinct peaks for non-industry ODs in 2015 and 2017 linked to European grant calls promoting regulatory engagement. Only six non-industry ODs led to marketing authorization, all post transfer to industry. Our findings indicate lower transition rates yet partial long-term convergence, highlighting the value of targeted grants and regulatory support.
No takes yet. Share an insight, caveat, or question.
Rosenberg et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: